IGC Pharma Inc
igcpharma.comWhat Do They Do?
Provides white-labeling services for customers’ formulations, sells wellness products to online consumers, and develops investigational treatments for Alzheimer’s disease.
10-K for FY2025, filed Jun 27, 2025Revenue in the renting business when the equipment is rented, and the terms of the agreement have been fulfilled during the period. Revenue…View ↗
Revenue from white labelling services consists of rebranding our formulations or the customer’s products as per the customer’s requirement.View ↗
IGC Pharma, a clinical-stage pharmaceutical company developing treatments for Alzheimer’s disease (AD) and related neurodegenerative…View ↗
How Do They Make Money?
White-labeling customers pay for rebranding work when the completed output is transferred to them; wellness-product sales are counted when goods are sold and delivered.
10-K for FY2025, filed Jun 27, 2025
-
10-K for FY2025, filed Jun 27, 2025
FY2025 revenue by product or service ↗
$1.3M
-
10-K for FY2025, filed Jun 27, 2025
$1.3M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Wellness and Lifestyle
Sold outright
|
8.9%
FY2022: 80%
|
Wellness and Lifestyle, FY2025
$113K Sources
|
Sold outright |
|
Tolling/White labeling service
Sold outright
10-K for FY2025, filed Jun 27, 2025 |
91%
FY2022: 11%
|
Tolling/White labeling service, FY2025
$1.2M Sources
|
Sold outright |
|
Other Revenue
|
0.0% |
Other Revenue, FY2025
$0 Sources
|
Who Are Their Customers?
Consumers can buy wellness products through the company’s online stores; white-labeling customers request rebranding of the company’s formulations or their own products.
10-K for FY2025, filed Jun 27, 2025
Do Revenues Turn Into Profits?
No. It lost $7.1M in FY2025.
10-K for FY2025, filed Jun 27, 2025
−$7.4MView ↗
10-K for FY2025, filed Jun 27, 2025
−$7.1MView ↗
10-K for FY2025, filed Jun 27, 2025
−$4.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$2.9MView ↗
- ▲ +84% (Loss)
- vs −$1.6M in Q2 FY2025
-
Nov 14, 2025
Sold manufacturing assets at its Vancouver facility
The buyer assumed certain employees and short-term leases; consideration included preferential-price manufacturing rights and a contingent share of proceeds from a resale.
Sources
8-K, filed Nov 14, 2025
As previously disclosed on October 1, 2025, Holi Hemp LLC (the “Seller”), a wholly owned subsidiary of IGC Pharma, Inc. (the “Company”)…View ↗
Growing. Revenue grew 42% in 4 years, from $898K in FY2021 to $1.3M in FY2025, about 9% a year.
Infrastructure wind-down
The earlier description includes infrastructure construction contracts alongside Life Sciences; the latest describes a single Life Sciences business and says Infrastructure is no longer actively managed separately.
10-K for FY2022, filed Jun 23, 2022 10-K for FY2025, filed Jun 27, 2025During fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life…View ↗
Who Do They Compete With?
Competes with Axsome Therapeutics, Otsuka, and Lundbeck
10-K for FY2025, filed Jun 27, 2025We are aware of other companies working to develop therapeutics for the treatment of AAD, including Axsome Therapeutics, Inc., which is…View ↗
Loading...
